Deep Learning Predicts Interval and Screening-detected Cancer from Screening Mammograms: A Case-Case-Control Study in 6369 Women

被引:18
|
作者
Zhu, Xun [1 ]
Wolfgruber, Thomas K. [1 ]
Leong, Lambert [1 ,2 ]
Jensen, Matthew [3 ]
Scott, Christopher [3 ]
Winham, Stacey [3 ]
Sadowski, Peter [2 ]
Vachon, Celine [3 ]
Kerlikowske, Karla [4 ,5 ]
Shepherd, John A. [1 ]
机构
[1] Univ Hawaii, Canc Ctr, Dept Epidemiol, 701 Ilalo St,Suite 522, Honolulu, HI 96813 USA
[2] Univ Hawaii Manoa, Dept Informat & Comp Sci, Honolulu, HI 96822 USA
[3] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA
[4] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA
[5] Univ Calif San Francisco, Dept Epidemiol Biostat, San Francisco, CA 94143 USA
关键词
BREAST DENSITY; RISK;
D O I
10.1148/radiol.2021203758
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background: The ability of deep learning (DL) models to classify women as at risk for either screening mammography-detected or interval cancer (not detected at mammography) has not yet been explored in the literature. Purpose: To examine- the ability of DL models to estimate the risk of interval and screening-detected breast cancers with and with-out clinical risk factors. Materials and Methods: This study was performed on 25 096 digital screening mammograms obtained from January 2006 to December 2013. The mammograms were obtained in 6369 women without breast cancer, 1609 of whom developed screening-detected breast cancer and 351 of whom developed interval invasive breast cancer. A DL model was trained on the negative mammograms to classify women into those who did not develop cancer and those who developed screening-detected cancer or interval invasive cancer. Model effectiveness was evaluated as a matched concordance statistic (C statistic) in a held-out 26% (1669 of 6369) test set. of the mammograms. Results: The C statistics and odds ratios for comparing patients with screening-detected cancer versus matched controls were 0.66 (95% CI: 0.63, 0.69) and 1.25 (95% CI: 1.17, 1.33), respectively, for the DL model, 0.62 (95% CI: 0.59, 0.65) and 2.14 (95% CI: 1.32, 3.45) for the clinical risk factors with the Breast Imaging Reporting and Data System (BI-RADS) density model, and 0.66 (95% CI: 0.63, 0.69) and 1.21 (95% CI: 1.13, 1.30) for the combined DL and clinical risk factors model. For comparing-patients with interval cancer versus controls, the C statistics and odds ratios were 0.64 (95% CI: 0.58, 0.71) and 1.26 (95% CI: 1.10, 1.45), respectively, for the DL model, 0.71 (95% CI: 0.65, 0.77) and 7.25 (95% CI: 2.94, 17.9) for the risk factors with BI-RADS -density (b rated vs non-b rated) model, and 0.72 (95% CI: 0.66, 0.78) and 1.10 (95% CI: 0.94, 1.29) for the combined DL and clinical risk factors model. The P values between the DL, BI-RADS, and combined model's ability to detect screen and interval cancer were.99,.002, and.03, respectively. Conclusion: The deep learning model outperformed in determining screening-detected cancer risk but underperformed for interval-cancer risk when compared with clinical risk factors including breast density. (C) RSNA, 2021
引用
收藏
页码:550 / 558
页数:9
相关论文
共 27 条
  • [21] Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study
    Stattin, Par
    Vickers, Andrew J.
    Sjoberg, Daniel D.
    Johansson, Robert
    Granfors, Torvald
    Johansson, Mattias
    Pettersson, Kim
    Scardino, Peter T.
    Hallmans, Goran
    Lilja, Hans
    EUROPEAN UROLOGY, 2015, 68 (02) : 207 - 213
  • [22] A nested case-control study of leukocyte mitochondrial DNA copy number and renal cell carcinoma in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
    Hofmann, Jonathan N.
    Hosgood, H. Dean, III
    Liu, Chin-San
    Chow, Wong-Ho
    Shuch, Brian
    Cheng, Wen-Ling
    Lin, Ta-Tsung
    Moore, Lee E.
    Lan, Qing
    Rothman, Nathaniel
    Purdue, Mark P.
    CARCINOGENESIS, 2014, 35 (05) : 1028 - 1031
  • [23] Acrylamide and Glycidamide Hemoglobin Adducts and Epithelial Ovarian Cancer: A Nested Case-Control Study in Nonsmoking Postmenopausal Women from the EPIC Cohort
    Obon-Santacana, Mireia
    Lujan-Barroso, Leila
    Travis, Ruth C.
    Freisling, Heinz
    Ferrari, Pietro
    Severi, Gianluca
    Baglietto, Laura
    Boutron-Ruault, Marie-Christine
    Fortner, Renee T.
    Ose, Jennifer
    Boeing, Heiner
    Menendez, Virginia
    Sanchez-Cantalejo, Emilio
    Chamosa, Saioa
    Huerta Castano, Jose Maria
    Ardanaz, Eva
    Khaw, Kay-Tee
    Wareham, Nick
    Merritt, Melissa A.
    Gunter, Marc J.
    Trichopoulou, Antonia
    Papatesta, Eleni-Maria
    Klinaki, Eleni
    Saieva, Calogero
    Tagliabue, Giovanna
    Tumino, Rosario
    Sacerdote, Carlotta
    Mattiello, Amalia
    Bueno-de-Mesquita, H. B.
    Peeters, Petra H.
    Onland-Moret, N. Charlotte
    Idahl, Annika
    Lundin, Eva
    Weiderpass, Elisabete
    Vesper, Hubert W.
    Riboli, Elio
    Duell, Eric J.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2016, 25 (01) : 127 - 134
  • [24] Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study
    Damiola, Francesca
    Pertesi, Maroulio
    Oliver, Javier
    Le Calvez-Kelm, Florence
    Voegele, Catherine
    Young, Erin L.
    Robinot, Nivonirina
    Forey, Nathalie
    Durand, Geoffroy
    Vallee, Maxime P.
    Tao, Kayoko
    Roane, Terrell C.
    Williams, Gareth J.
    Hopper, John L.
    Southey, Melissa C.
    Andrulis, Irene L.
    John, Esther M.
    Goldgar, David E.
    Lesueur, Fabienne
    Tavtigian, Sean V.
    BREAST CANCER RESEARCH, 2014, 16 (03):
  • [25] Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study)
    Murad, Ali S.
    Down, Liz
    Smith, George Davey
    Donovan, Jenny L.
    Lane, Janet Athene
    Hamdy, Freddie C.
    Neal, David E.
    Martin, Richard M.
    INTERNATIONAL JOURNAL OF CANCER, 2011, 128 (06) : 1442 - 1448
  • [26] Possible Association between the Use of Proton Pump Inhibitors and H2 Receptor Antagonists, and Esophageal Cancer: A Nested Case-Control Study Using a Korean National Health Screening Cohort
    Choi, Hyo Geun
    Lee, Hong Kyu
    Kang, Ho Suk
    Lim, Hyun
    Kim, Joo-Hee
    Kim, Ji Hee
    Kim, Nan Young
    Cho, Seong-Jin
    Nam, Eun Sook
    Min, Kyueng-Whan
    Kwon, Mi Jung
    PHARMACEUTICALS, 2022, 15 (05)
  • [27] Obese men have more advanced and more aggressive prostate cancer at time of surgery than non-obese men after adjusting for screening PSA level and age: results from two independent nested case-control studies
    Parker, A. S.
    Thiel, D. D.
    Bergstralh, E.
    Carlson, R. E.
    Rangel, L. J.
    Joseph, R. W.
    Diehl, N.
    Karnes, R. J.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2013, 16 (04) : 352 - 356